Singulex is a technology company.
Singulex is revolutionizing immunodiagnostics to transform healthcare with its Sgx Clarity® system, powered by Single Molecule Counting technology.
Singulex has raised $68.0M across 4 funding rounds.
Key people at Singulex.
Singulex has raised $68.0M in total across 4 funding rounds.
Key people at Singulex.
Singulex is a commercial-stage biotechnology company specializing in next-generation immunodiagnostics (NGI) powered by its proprietary Single Molecule Counting (SMC) technology, which delivers up to 1000 times greater sensitivity than conventional immunoassays for precise biomarker measurement.[1][2][3] The company develops the Singulex Clarity system, a fully automated in vitro diagnostics platform, along with assays for cardiovascular, oncology, infectious, inflammatory, neurodegenerative, and autoimmune diseases; it serves clinicians, physicians, patients, pharmaceutical R&D labs, CROs, and academic institutions through lab testing services (over 3 million tests on 780,000+ patients), research-use-only Erenna systems, and clinical diagnostics.[1][2][3][5] Singulex addresses the problem of undetectable low-abundance biomarkers (e.g., cardiac troponin I, cytokines at femtogram/mL levels), enabling proactive health management, earlier disease detection, reduced healthcare costs, and accelerated therapeutic discovery over reactive treatment.[1][2][3]
Growth momentum includes CE marking for the Clarity system and assays in 2017 (commercially available in Europe), a 2017 FDA 510(k) submission for U.S. clearance (anticipated 2018 commercialization), and ongoing development of point-of-care platforms and expanded assays.[1][2][4]
Singulex emerged as a pioneer in single-molecule detection technology, founded to commercialize SMC for clinical diagnostics and research, though exact founding year and founders' names are not detailed in available sources.[1][3] Leadership includes experienced executives like John (prior roles at Chiron Diagnostics, Bayer, Baxter, with 60+ publications, 15 patents, and SBIR grants), Jeff (Ph.D. in Bioengineering from UC San Diego), and Mr. Vogt (25 years at Mallinckrodt, Chemical Engineering degrees).[1] The idea stemmed from advancing immunoassay sensitivity to detect previously undetectable biomarkers in complex samples without protein stripping, fueling biomarker validation for drug safety/efficacy and diseases like cardiovascular, Alzheimer's, oncology, and diabetes.[3][5]
Early traction involved launching research-use-only Erenna Immunoassay Systems for pharma/academia, building a U.S.-based clinical lab (3M+ tests), and securing CE marks in 2017, with FDA submission marking a pivotal shift to automated clinical platforms.[2][3][4]
Singulex rides the wave of precision medicine and biomarker-driven diagnostics, where ultra-sensitive detection shifts healthcare from reactive treatment to proactive management amid rising chronic disease burdens (e.g., cardiovascular, oncology).[1][2][3] Timing aligns with regulatory progress (2017 CE marks, FDA submission) and demand for high-sensitivity troponin tests, as studies validate SMC's role in identifying coronary artery disease severity in stable patients.[6] Market forces like aging populations, cost pressures, and pharma's need for better R&D tools favor Singulex, influencing the ecosystem by enabling new therapeutic discoveries and influencing standards in immunodiagnostics.[3][5]
Singulex is poised for U.S. market entry post-FDA clearance, expanding Clarity assays and point-of-care platforms to global labs and beyond-clinical uses, potentially scaling tests exponentially.[1][2][4] Trends like AI-integrated diagnostics and personalized wellness (e.g., CVMedHome) will shape growth, amplifying its influence in transforming immunodiagnostics from niche research to mainstream healthcare disruption.[3][5] As biomarker precision becomes table stakes, Singulex's SMC edge positions it to redefine early detection, much like its foundational promise to "see what others can’t."[6]
Singulex has raised $68.0M in total across 4 funding rounds.
Singulex's investors include Dimension Capital, OrbiMed, Polaris Partners, Section 32.
Singulex has raised $68.0M across 4 funding rounds. Most recently, it raised $15.0M Series G in June 2013.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2013 | $15.0M Series G | Dimension Capital, OrbiMed, Polaris Partners, Section 32 | |
| Mar 1, 2012 | $15.0M Series F | Dimension Capital, OrbiMed, Polaris Partners, Section 32 | |
| Jan 1, 2009 | $19.0M Series E | Dimension Capital, OrbiMed, Polaris Partners, Section 32 | |
| Jun 1, 2007 | $19.0M Series D | Dimension Capital, OrbiMed, Polaris Partners, Section 32 |
